Impact of self-financed rotavirus vaccines on hospital stays and costs in Spain after a 3-year introductory period
| Autor: | J.M. Tenías-Burillo, O. Redondo-González, J. Ruiz-Gonzalo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Rotavirus Pediatrics medicine.medical_specialty Epidemiology 030106 microbiology Rotavirus vaccination medicine.disease_cause Vaccines Attenuated Rotavirus Infections 03 medical and health sciences 0302 clinical medicine Medicine Humans 030212 general & internal medicine business.industry Rotavirus Vaccines Odds ratio Length of Stay Hospital costs Spain length of stay rotavirus vaccines Original Papers Confidence interval Gastroenteritis Vaccination Hospitalization Infectious Diseases Spain business |
| Zdroj: | Epidemiol Infect EPIDEMIOLOGY AND INFECTION r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) r-FISABIO. Repositorio Institucional de Producción Científica instname |
| ISSN: | 0950-2688 |
| Popis: | SUMMARYVaccination has reduced rotavirus hospitalizations by 25% in European regions with low–moderate vaccine availability. We aimed to quantify the reduction in hospital costs after the longest period in which Rotarix® and Rotateq® were simultaneously commercially available in Spain. Cases, length of stay (LOS), and diagnosis-related groups (DRGs) were retrieved from the Minimum Basic Data Set. Healthcare expenditure was estimated through the cost accounting system Gescot®. DRGs were clustered: I, non-bacterial gastroenteritis with complications; II, without complications; III, requiring surgical/other procedures or neonatal cases (highest DRG weights). Comparisons between pre (2003–2005)- and post-vaccine (2007–2009) hospital stays and costs by DRG group were made. Rotaviruses were the most common agents of specific-coded gastroenteritis (N = 1657/5012). LOS and extended LOS of rotaviruses fell significantly in 2007–2009 (β-coefficient = −0·43, 95% confidence intervals (95% CI) −0·68 to −0·17; and odds ratio 0·62, 95% CI 0·50–0·76, respectively). Overall, costs attributable to rotavirus hospitalizations fell approximately €244 per patient (95% CI −365 to −123); the decrease in DRG group III was €2269 per patient (95% CI −4098 to −380). We concluded modest savings in hospital costs, largely attributable to cases with higher DRG weights, and a faster recovery. A universal rotavirus vaccination program deserves being re-evaluated, regarding its potential high impact on both at-risk children and societal costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|